Poor outcome in patients treated with brachytherapy for diffuse in-stent restenosis. The role of additional stenting despite prolonged antiplatelet therapy

Dennis Zavalloni, Marco Rossi, Guido Belli, Melania Scatturin, Emanuela Morenghi, Federica Marsico, Giampiero Catalano, Giovanni Tosi, Paolo Pagnotta, Patrizia Presbitero

Research output: Contribution to journalArticle

Abstract

Background. Brachytherapy (IBT) has been the first effective treatment of in-stent restenosis (ISR). However, when IBT is associated with additional stenting, high rates of late thrombosis have been observed. Even though prolongation of a double antiplatelet therapy seems to have overcome this problem, studies analyzing whether additional stenting still remains a negative prognostic factor for restenosis are lacking. Aim. To evaluate outcomes of patients treated for ISR with or without additional stenting and IBT followed by prolonged antiplatelet therapy. Methods. Seventy-seven consecutive patients treated with beta radiation in 89 lesions with ISR were analyzed according to the need for deploying additional stents: 73 lesions were treated without additional stents (Group 1) and 16 lesions with one or more new stents (Group 2) because of suboptimal results or flow-limiting dissections. Double antiplatelet therapy was administered for 12 months. An angiographic follow-up was scheduled after 6 months. P-values <0.05 were considered significant. Results. Restenosis rates were 31.5% (23/73) and 62.5% (10/16) in Group 1 (G1) and Group 2 (G2), respectively (p = 0.02). The two groups did not differ for late vessel thrombosis (8 in G1 and 2 in G2). In G2, high rates of recurrence were observed in the additional stent (6/16, 37.5%; p = 0.02 versus edge restenosis and in old stent recurrence in both G1 and G2). Conclusions. The association of additional stenting with brachytherapy in treatment of ISR is characterized by poor outcomes, even if a prolonged antiplatelet therapy has been administered. These results are related to high restenosis rates observed in the additional stent.

Original languageEnglish
Pages (from-to)598-602
Number of pages5
JournalJournal of Invasive Cardiology
Volume17
Issue number11
Publication statusPublished - Nov 2005

Fingerprint

Brachytherapy
Stents
Therapeutics
Thrombosis
Beta Particles
Recurrence
Dissection

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Poor outcome in patients treated with brachytherapy for diffuse in-stent restenosis. The role of additional stenting despite prolonged antiplatelet therapy. / Zavalloni, Dennis; Rossi, Marco; Belli, Guido; Scatturin, Melania; Morenghi, Emanuela; Marsico, Federica; Catalano, Giampiero; Tosi, Giovanni; Pagnotta, Paolo; Presbitero, Patrizia.

In: Journal of Invasive Cardiology, Vol. 17, No. 11, 11.2005, p. 598-602.

Research output: Contribution to journalArticle

Zavalloni, Dennis ; Rossi, Marco ; Belli, Guido ; Scatturin, Melania ; Morenghi, Emanuela ; Marsico, Federica ; Catalano, Giampiero ; Tosi, Giovanni ; Pagnotta, Paolo ; Presbitero, Patrizia. / Poor outcome in patients treated with brachytherapy for diffuse in-stent restenosis. The role of additional stenting despite prolonged antiplatelet therapy. In: Journal of Invasive Cardiology. 2005 ; Vol. 17, No. 11. pp. 598-602.
@article{7aa5610786804438af33b4a607b58f16,
title = "Poor outcome in patients treated with brachytherapy for diffuse in-stent restenosis. The role of additional stenting despite prolonged antiplatelet therapy",
abstract = "Background. Brachytherapy (IBT) has been the first effective treatment of in-stent restenosis (ISR). However, when IBT is associated with additional stenting, high rates of late thrombosis have been observed. Even though prolongation of a double antiplatelet therapy seems to have overcome this problem, studies analyzing whether additional stenting still remains a negative prognostic factor for restenosis are lacking. Aim. To evaluate outcomes of patients treated for ISR with or without additional stenting and IBT followed by prolonged antiplatelet therapy. Methods. Seventy-seven consecutive patients treated with beta radiation in 89 lesions with ISR were analyzed according to the need for deploying additional stents: 73 lesions were treated without additional stents (Group 1) and 16 lesions with one or more new stents (Group 2) because of suboptimal results or flow-limiting dissections. Double antiplatelet therapy was administered for 12 months. An angiographic follow-up was scheduled after 6 months. P-values <0.05 were considered significant. Results. Restenosis rates were 31.5{\%} (23/73) and 62.5{\%} (10/16) in Group 1 (G1) and Group 2 (G2), respectively (p = 0.02). The two groups did not differ for late vessel thrombosis (8 in G1 and 2 in G2). In G2, high rates of recurrence were observed in the additional stent (6/16, 37.5{\%}; p = 0.02 versus edge restenosis and in old stent recurrence in both G1 and G2). Conclusions. The association of additional stenting with brachytherapy in treatment of ISR is characterized by poor outcomes, even if a prolonged antiplatelet therapy has been administered. These results are related to high restenosis rates observed in the additional stent.",
author = "Dennis Zavalloni and Marco Rossi and Guido Belli and Melania Scatturin and Emanuela Morenghi and Federica Marsico and Giampiero Catalano and Giovanni Tosi and Paolo Pagnotta and Patrizia Presbitero",
year = "2005",
month = "11",
language = "English",
volume = "17",
pages = "598--602",
journal = "Journal of Invasive Cardiology",
issn = "1042-3931",
publisher = "HMP Communications",
number = "11",

}

TY - JOUR

T1 - Poor outcome in patients treated with brachytherapy for diffuse in-stent restenosis. The role of additional stenting despite prolonged antiplatelet therapy

AU - Zavalloni, Dennis

AU - Rossi, Marco

AU - Belli, Guido

AU - Scatturin, Melania

AU - Morenghi, Emanuela

AU - Marsico, Federica

AU - Catalano, Giampiero

AU - Tosi, Giovanni

AU - Pagnotta, Paolo

AU - Presbitero, Patrizia

PY - 2005/11

Y1 - 2005/11

N2 - Background. Brachytherapy (IBT) has been the first effective treatment of in-stent restenosis (ISR). However, when IBT is associated with additional stenting, high rates of late thrombosis have been observed. Even though prolongation of a double antiplatelet therapy seems to have overcome this problem, studies analyzing whether additional stenting still remains a negative prognostic factor for restenosis are lacking. Aim. To evaluate outcomes of patients treated for ISR with or without additional stenting and IBT followed by prolonged antiplatelet therapy. Methods. Seventy-seven consecutive patients treated with beta radiation in 89 lesions with ISR were analyzed according to the need for deploying additional stents: 73 lesions were treated without additional stents (Group 1) and 16 lesions with one or more new stents (Group 2) because of suboptimal results or flow-limiting dissections. Double antiplatelet therapy was administered for 12 months. An angiographic follow-up was scheduled after 6 months. P-values <0.05 were considered significant. Results. Restenosis rates were 31.5% (23/73) and 62.5% (10/16) in Group 1 (G1) and Group 2 (G2), respectively (p = 0.02). The two groups did not differ for late vessel thrombosis (8 in G1 and 2 in G2). In G2, high rates of recurrence were observed in the additional stent (6/16, 37.5%; p = 0.02 versus edge restenosis and in old stent recurrence in both G1 and G2). Conclusions. The association of additional stenting with brachytherapy in treatment of ISR is characterized by poor outcomes, even if a prolonged antiplatelet therapy has been administered. These results are related to high restenosis rates observed in the additional stent.

AB - Background. Brachytherapy (IBT) has been the first effective treatment of in-stent restenosis (ISR). However, when IBT is associated with additional stenting, high rates of late thrombosis have been observed. Even though prolongation of a double antiplatelet therapy seems to have overcome this problem, studies analyzing whether additional stenting still remains a negative prognostic factor for restenosis are lacking. Aim. To evaluate outcomes of patients treated for ISR with or without additional stenting and IBT followed by prolonged antiplatelet therapy. Methods. Seventy-seven consecutive patients treated with beta radiation in 89 lesions with ISR were analyzed according to the need for deploying additional stents: 73 lesions were treated without additional stents (Group 1) and 16 lesions with one or more new stents (Group 2) because of suboptimal results or flow-limiting dissections. Double antiplatelet therapy was administered for 12 months. An angiographic follow-up was scheduled after 6 months. P-values <0.05 were considered significant. Results. Restenosis rates were 31.5% (23/73) and 62.5% (10/16) in Group 1 (G1) and Group 2 (G2), respectively (p = 0.02). The two groups did not differ for late vessel thrombosis (8 in G1 and 2 in G2). In G2, high rates of recurrence were observed in the additional stent (6/16, 37.5%; p = 0.02 versus edge restenosis and in old stent recurrence in both G1 and G2). Conclusions. The association of additional stenting with brachytherapy in treatment of ISR is characterized by poor outcomes, even if a prolonged antiplatelet therapy has been administered. These results are related to high restenosis rates observed in the additional stent.

UR - http://www.scopus.com/inward/record.url?scp=33646012042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646012042&partnerID=8YFLogxK

M3 - Article

C2 - 16264205

AN - SCOPUS:33646012042

VL - 17

SP - 598

EP - 602

JO - Journal of Invasive Cardiology

JF - Journal of Invasive Cardiology

SN - 1042-3931

IS - 11

ER -